Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis P Garrison

Showing results (71-80 of 190) with videos related to

Pageof 19
Sort By:
Journal of Medical Economics|August 14, 2012
Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United StatesRoman Casciano, Maruit Chulikavit, Allison Perrin, et al.
Health Economics|June 26, 2019
Do cancer treatments have option value? Real-world evidence from metastatic melanomaMeng Li, Anirban Basu, Caroline S Bennette, et al.
Molecular Oncology|March 21, 2012
Paying for personalized care: cancer biomarkers and comparative effectivenessRahber Thariani, David L Veenstra, Josh J Carlson, et al.
Value in Health Regional Issues|February 22, 2023
Estimating the Potential Economic Impact of Tissue Valve Replacement for Heart Valve Disease in China: Patient-Level and Population-Level Cost-Benefit Simulation AnalysesBruce Wang, Elizabeth Wu, Dirk Rassloff, et al.
Applied Health Economics and Health Policy|February 5, 2024
Evidence Synthesis and Linkage for Modelling the Cost-Effectiveness of Diagnostic Tests: Preliminary Good Practice RecommendationsBethany Shinkins, A Joy Allen, James Karichu, et al.
Journal of Medical Economics|July 12, 2011
Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk scoreSean D Sullivan, Louis P Garrison, Harald Rinde, et al.
Frontiers in Pharmacology|April 25, 2022
Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy ImplicationsAndrás Incze, Zoltán Kaló, Jaime Espín, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|December 27, 2016
Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-upLouis P Garrison, Marita R Zimmermann, Christopher H Young, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 1, 2025
Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare DiseasesWalter Toro, Min Yang, Anish Patel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2007
Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force reportLouis P Garrison, Peter J Neumann, Pennifer Erickson, et al.
Pageof 19

Showing results (71-80 of 190) with videos related to

Sort By:
Pageof 19
Journal of Medical Economics|August 14, 2012
Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United StatesRoman Casciano, Maruit Chulikavit, Allison Perrin, et al.
Health Economics|June 26, 2019
Do cancer treatments have option value? Real-world evidence from metastatic melanomaMeng Li, Anirban Basu, Caroline S Bennette, et al.
Molecular Oncology|March 21, 2012
Paying for personalized care: cancer biomarkers and comparative effectivenessRahber Thariani, David L Veenstra, Josh J Carlson, et al.
Value in Health Regional Issues|February 22, 2023
Estimating the Potential Economic Impact of Tissue Valve Replacement for Heart Valve Disease in China: Patient-Level and Population-Level Cost-Benefit Simulation AnalysesBruce Wang, Elizabeth Wu, Dirk Rassloff, et al.
Applied Health Economics and Health Policy|February 5, 2024
Evidence Synthesis and Linkage for Modelling the Cost-Effectiveness of Diagnostic Tests: Preliminary Good Practice RecommendationsBethany Shinkins, A Joy Allen, James Karichu, et al.
Journal of Medical Economics|July 12, 2011
Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk scoreSean D Sullivan, Louis P Garrison, Harald Rinde, et al.
Frontiers in Pharmacology|April 25, 2022
Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy ImplicationsAndrás Incze, Zoltán Kaló, Jaime Espín, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|December 27, 2016
Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-upLouis P Garrison, Marita R Zimmermann, Christopher H Young, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 1, 2025
Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare DiseasesWalter Toro, Min Yang, Anish Patel, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2007
Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force reportLouis P Garrison, Peter J Neumann, Pennifer Erickson, et al.
Pageof 19